Telix Pharmaceuticals Forecast, price target & analysts
Telix Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Telix Pharmaceuticals Classifications & Recommendation
Telix Pharmaceuticals Price Target
| Target Price | A$22.44 |
| Price | A$15.90 |
| Potential |
41.13%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Telix Pharmaceuticals 2027 .
The average Telix Pharmaceuticals target price is A$22.44.
This is
41.13%
register free of charge
A$32.55
104.72%
register free of charge
A$19.19
20.69%
register free of charge
|
|
| A rating was issued by 18 analysts: 15 Analysts recommend Telix Pharmaceuticals to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Telix Pharmaceuticals stock has an average upside potential 2027 of
41.13%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million A$ | 803.79 | 989.56 |
| 55.61% | 23.11% | |
| Net Margin | -0.89% | 1.83% |
| 113.60% | 306.30% |
17 Analysts have issued a sales forecast Telix Pharmaceuticals 2026 . The average Telix Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
16 Telix Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Telix Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | -0.02 | 0.05 |
| 120.00% | 350.00% | |
| P/E | 298.15 | |
| EV/Sales | 5.74 |
16 Analysts have issued a Telix Pharmaceuticals forecast for earnings per share. The average Telix Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Telix Pharmaceuticals...
Current Telix Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WEDBUSH SECURITIES INC. |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| CANACCORD GENUITY |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| TAYLOR COLLISON |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 21 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 14 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Sep 04 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
WEDBUSH SECURITIES INC.:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
CANACCORD GENUITY:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
TAYLOR COLLISON:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 21 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 14 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Sep 04 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
